

IHI Call Days | Call 12

Therapeutic and non-therapeutic interventions for addressing anti-microbial resistance (AMR)

Contact person name: Jonathan Jones

Organisation: CPI

E-mail: Jonathan.jones@uk-cpi.com



Innovate
UK





Tackling AMR through integrated diagnostics & therapeutics

Challenge

- AMR causes 1.27M* deaths annually with urgent need for personalised infection treatment
- Current systems lack integration between diagnostics and therapeutics

Vision

- Develop a suite of diagnostic and therapeutic tools for bacterial infections
- Enable precision treatment and reduce antibiotic misuse

IHI Alignment: SO2 (Integrating fragmented health research and innovation)


A collaborative path to Innovation

Approach

- **Diagnostics:** Rapid, real-time pathogen identification
- **Therapeutics:** Diverse modalities (phage, RNA, mABs, vaccines & small molecules)
- **Process Development:** Scalable, regulated and digitally enabled
- **Integration:** Embed solutions into European healthcare systems

Collaboration Needs

- Diagnostic innovators
- Therapeutic developers (academia, SMEs, industry)
- Digital tech partners
- Healthcare providers & regulators




Transforming AMR Response across Europe

Expected Outcomes

- Precision Infection Treatment
- Strengthened EU health industry competitiveness
 - Faster market translation of novel modalities
- Improved patient outcomes & public health resilience

Let's Connect

If you have a technology, capability, or interest in driving the integration of diagnostics and therapeutics to tackle antimicrobial resistance, we'd love to explore how we can work together to facilitate meaningful change. Let's discuss how your expertise can contribute to this collaborative effort and help shape the future of AMR treatment





Jonathan Jones

Jonathan Jones

Manager – Microbial Upstream

Jonathan.Jones@uk-cpi.com

+44 (0)7584054883

For more information about CPI's capabilities. Please visit www.uk-cpi.com

